JRJeffrey V. Ravetch

Jeffrey V. Ravetch

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Recognitions

Top Cited Scholar (2025)

Jeffrey V. Ravetch has a total of 474 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mechanisms of antibody-mediated enhancement of immune responses

    by Melissa Cipolla, Andrew J. MacLean, Brianna Hernandez, Gabriela S. Silva Santos, Leonidas Stamatatos, Anna Gazumyan, Harald Hartweger, Julia Merkenschlager, Stylianos Bournazos, Jeffrey V. Ravetch, et al.

    Immune memory responses are rapid and qualitatively distinct from primary responses. They typically develop in the presence of antigen-experienced memory T and B cells and preexisting antibodies. Although the contribution of T and B cells to recall responses is well defined, the contribution of antibody “memory” and the mechanisms by which preexisting antibodies modulate the development of germinal center (GC) and plasma cell responses is not precisely understood. Here, we report on mechanisms that mediate antibody enhancement of GC and plasmablast (PB) compartments, and the parallel process by which antibodies change the affinity threshold for B cell recruitment into immune responses. The data indicate that antibody-mediated enhancement of GC and PB responses is Fc gamma receptor (FcγR) dependent and largely complement receptor 1 and 2 (CR1/2) independent. In contrast, the reduction in the affinity threshold for GC entry is independent of both FcγRs and CR1/2.

  • Open Access

    Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition

    by Yueyun Pan, Shengduo Pei, Heng Liang, Kajsa Westberg, Lars Nitschke, Xinsong Chen, Yinda Yu, Ning He, Qirong Lin, Li Lei, et al.

    Immunotherapy is now an established and efficient treatment option for many cancer patients. However, a proportion of patients still experience poor outcomes due to treatment resistance. Thus, a clear understanding of key mechanisms of resistance is needed for the development of new treatments. Here, we employ mouse models to explore an immunotherapeutic approach based on anti-MARCO (αMARCO) and anti-PD-L1 (αPD-L1) antibody-mediated targeting of tumor-associated macrophages (TAM). We demonstrate that effective immunotherapy relies on a functional endosomal pattern recognition machinery. We determine that endosomal Toll-like receptors (TLR), specifically TLR9, precondition macrophages to respond to αMARCO treatment by regulating the transcription of inflammasome components. Absence of TLRs renders TAMs unresponsive to treatment while retaining an immunosuppressive phenotype. Thus, we uncover the intracellular TLR signalling as a feature of immunotherapy efficacy, required to sensitise TAMs to treatment, and indicate that TLR targeting could be exploited to improve immunotherapeutic outcomes.

  • Open Access

    Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infection

    by Masao Hashimoto, Tahseen H. Nasti, Hyun-Tak Jin, Melissa Bu, Koichi Araki, Junghwa Lee, Rajesh M. Valanparambil, Akil Akhtar, Mohammad Affan Khan, Zhipeng Peng, et al.

    Anti-programmed cell death 1 (PD-1) antibody therapy is now widely used in various cancers. However, the role of the antibody Fc region in PD-1 directed immunotherapy is not well understood. Preclinical studies commonly use species-mismatched rat anti-mouse antibodies, which may not accurately reflect antibody-Fc gamma receptor (FcγR) interactions. Here, we used mouse anti-mouse PD-1 antibodies to investigate how the Fc region influences therapeutic efficacy for enhancing CD8 T cell responses using mouse models of chronic lymphocytic choriomeningitis virus infection and CT26 tumors. Treatment with these mouse anti-mouse PD-1 antibodies caused preferential depletion of PD-1+ virus-specific CD8 T cells in the liver, resulting in increased viral titers. These effects of mouse anti-PD-1 antibodies were Fc dependent since mutating the Fc region to block FcγR interaction prevented PD-1+ CD8 T cell depletion and resulted in effective immunotherapy. Using mice lacking activating FcγR III or inhibitory FcγR IIb, we found that depletion of PD-1+ CD8 T cells was mediated via activating FcγR III. Furthermore, we determined that phagocytic cells, not natural killer cells, were the in vivo effectors that mediated depletion of PD-1+ CD8 T cells. Similar depletion of tumor-specific CD8 T cells and reduced tumor control were observed in the CT26 model with Fc-intact mouse anti-mouse PD-1 treatment. These findings highlight potential negative effects of Fc-functional anti-PD-1 antibodies in therapies for liver cancer, liver metastases, and chronic hepatotropic viral infections. Conversely, FcγR-mediated depletion could benefit “agonistic” anti-PD-1 antibodies for treatment of autoimmunity. Our research emphasizes the importance of Fc region in tailoring PD-1 therapies for diverse clinical applications.


  • Open Access

    Fc receptor dependent and independent mechanisms of antibody-mediated enhancement of immune responses

    by Melissa Cipolla, Andrew J. MacLean, Brianna Hernandez, Gabriela S. Silva Santos, Leonidas Stamatatos, Anna Gazumyan, Harald Hartweger, Julia Merkenschlager, Stylianos Bournazos, Jeffrey V. Ravetch, et al.

    Immune memory responses are rapid and qualitatively distinct from primary responses. They typically develop in the presence of antigen-experienced memory T and B cells and pre-existing antibodies. Although the contribution of T and B cells to recall responses is well defined, the contribution of antibody “memory” and the mechanisms by which pre-existing antibodies modulate the development of germinal center and plasma cell responses is not precisely understood. Here we report on mechanisms that mediate antibody enhancement of germinal center (GC) and plasmablast (PB) compartments, and the parallel process by which they change the affinity threshold for B cell recruitment into immune responses. The data indicate that antibody-mediated enhancement of GC and PB responses is Fc gamma receptor (FcγR) dependent and largely complement receptor 1 and 2 (CR1/2) independent. In contrast, the reduction in the affinity threshold for GC entry is independent of both FcγRs and CR1/2. Summary: Cipolla et al. show that antibody can modulate immune responses via both Fc gamma receptor dependent and independent mechanisms. These mechanisms influence both the magnitude and composition of the germinal center response.

  • Open Access

    Antibody-lectin chimeras for glyco-immune checkpoint blockade

    by Jessica C. Stark, Melissa A. Gray, Itziar Ibarlucea-Benitez, Marta Lustig, Annalise Bond, Brian Cho, Ishika Govil, Tran Luu, Megan J. Priestley, Tim S. Veth, et al.

    Despite the curative potential of checkpoint blockade immunotherapy, many patients remain unresponsive to existing treatments. Glyco-immune checkpoints, which involve interactions of cell-surface glycans with lectin, or glycan-binding, immunoreceptors, have emerged as prominent mechanisms of immune evasion and therapeutic resistance in cancer. Here, we describe antibody-lectin chimeras (AbLecs), a modular system for glyco-immune checkpoint blockade. AbLecs are bispecific antibody-like molecules comprising a cell-targeting antibody domain and a lectin ‘decoy receptor’ domain that directly binds glycans and blocks their ability to engage inhibitory lectin receptors. AbLecs potentiate cancer cell destruction by primary human immune cells in vitro and reduce tumour burden in a humanized, immunocompetent mouse model, outperforming most existing therapies and combinations tested. By targeting a distinct axis of immunological regulation, AbLecs synergize with blockade of established immune checkpoints. AbLecs can be readily designed to target numerous tumours and immune cell subsets as well as glyco-immune checkpoints, thus representing a potential modality for cancer immunotherapy.


  • Open Access

    Asymmetrically glycosylated IgG1 antibodies are universal and drive human disease

    by Tala Azzam, Stylianos Bournazos, Hasret Gunduz, Trevor Adams, Maria W. Flowers, Emily G. Niejadlik, Veasna Duong, Trenton J. Brown, Anne M. Roberts, Diego E. Sastre, et al.

    IgG antibodies have a conserved N-linked glycan on residue Asn297 of the homodimeric Fc region that modulates antibody-mediated effector functions. These effects on the immune response are reflected in correlations between IgG glycans and numerous infectious and autoimmune diseases. However, current studies fail to characterize these Asn297-linked glycans comprehensively, relying on glycan release methods. Here, we develop an intact LC/MS method to glycoprofile polyclonal IgG antibodies while preserving the Fc glycan spatial pairing. We analyze plasma samples from healthy and virally infected individuals and find that all individuals have asymmetrically glycosylated IgGs—the glycans on each of the Fc protomers are not identical. We find that the previously observed association between IgG afucosylation and severe dengue disease is due to asymmetric monofucosylation of IgGs, not symmetric afucosylation. Finally, we engineer monofucosylated IgG1s which are indistinguishable from afucosylated IgG1s in binding to FcγRIIIA in vitro and inducing effector functions in vivo.


  • The anti-inflammatory activity of IgG is enhanced by co-engagement of type I and II Fc receptors

    by Andrew T. Jones, Alessandra E. Marino, Tetyana Martynyuk, Stylianos Bournazos, Jeffrey V. Ravetch

    Intravenous immunoglobulin (IVIG) administered at high doses is used to treat a wide array of autoimmune diseases. Studies in murine models have identified that the anti-inflammatory activity of IVIG is dependent on sialylation of the N-linked glycan on the CH2 domain of immunoglobulin G (IgG), the type I IgG inhibitory Fc receptor FcγRIIB, and the type II Fc receptor dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN). We hypothesized that DC-SIGN, a C-type lectin, may directly interact with glycans on FcγRIIB, augmenting its ability to bind sialylated IgG. We found that Fc-engineering sialylated IgG1 to enhance its affinity for FcγRIIB resulted in a molecule that was more potent than IVIG in reducing the inflammatory sequelae of antibody or T cell–mediated autoimmune diseases, providing the basis for a class of potent anti-inflammatory therapeutics.


  • Open Access

    Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer

    by Juan C. Osorio, David A. Knorr, Polina Weitzenfeld, Lucas Blanchard, Ning Yao, Maria Baez, Carlo Sevilla, Meghan DiLillo, Jahan Rahman, Ved P. Sharma, et al.


  • Open Access

    FcγRIIIa is a noncanonical costimulatory molecule for CD8 T cells

    by Kevin S. Kao, Nicole L. Pihlstrom, Emily G. Niejadlik, Tineke Cantaert, Rafi Ahmed, Jeffrey V. Ravetch, Stylianos Bournazos

    A critical component of the function of IgG antibodies is their capacity to engage specialized cellular receptors, Fcγ receptors (FcγRs), expressed on effector leukocytes. Highlighting the importance of FcγR-mediated signaling in the regulation of the fate, activation, and differentiation status of leukocytes, FcγRs are ubiquitously expressed by nearly all leukocyte populations. Here, we report that while at steady state, T cells are negative for all classes of FcγRs, CD8 T cells specifically induce the expression of the activating FcγR, FcγRIIIa, in response to viral infection in cohorts of COVID-19 and dengue patients, as well as in virus infection models using FcγR humanized mouse strains. In in vivo mechanistic studies, we demonstrate that induction of FcγRIIIa expression on effector CD8 T cells follows a well-defined trajectory that closely tracks the course and magnitude of the immune response, while immune resolution is characterized by receptor downregulation. Uniquely to these CD8 T cells, FcγRIIIa crosslinking alone is paradoxically insufficient to elicit T cell activation and cytotoxicity. However, when coupled with T cell receptor (TCR) stimulation, it results in synergistic cellular activation and, compensates for the downregulation of canonical costimulatory molecules on terminal effector CD8 T cells. These results reveal a previously unappreciated role for FcγRIIIa as a unique costimulatory molecule that synergizes with TCR signaling to lower the effective threshold required for CD8 T cell activation, highlighting the role of virally induced antibodies in modulating CD8 effector cell responses.


  • Open Access

    The mechanistic basis for interprotomer deglycosylation of antibodies by corynebacterial IgG-specific endoglycosidases

    by Diego E. Sastre, Stylianos Bournazos, Maros Huliciak, Barbara Ann C. Grace, E. Josephine Boder, Jonathan Du, Nazneen Sultana, Tala Azzam, Trenton J. Brown, Maria W. Flowers, et al.

    Corynebacterium diphtheriae clade species secrete single-domain endo-β-N-acetylglucosaminidases (ENGases) that specifically bind to human IgG antibodies and hydrolyze their N297-linked glycans. Here, we define the molecular mechanisms of IgG-specific deglycosylation for the entire family of corynebacterial IgG-specific ENGases, including but not limited to CU43 and CM49. By solving the crystal structure of CU43 in a 1:1 complex with the IgG1 Fc region, combined with targeted and saturation mutagenesis analysis and activity measurements using engineered antibodies, we establish an inter-protomeric mechanism of recognition and deglycosylation of IgG antibodies. Using in silico modeling, small-angle X-ray scattering and saturation mutagenesis we determine that CM49 uses a unique binding site on the Fc region, to process N297-linked glycans. Moreover, we demonstrate that CU43 treatment is highly effective in abrogating Fc effector functions in humanized mouse models, while preserving the neutralizing capacity of anti-influenza IgG antibodies, thereby conferring protection against lethal influenza challenge.